<DOC>
	<DOCNO>NCT00399659</DOCNO>
	<brief_summary>This study evaluate safety efficacy Tegaserod opioid-induced constipation ( OIC ) patient non-cancer pain . Patients enter study PRIOR core study ( CHTF919N2201 ) interim analysis ( IA ) receive treatment follow : Patients tegaserod 6 mg twice daily ( b.i.d . ) 12 mg daily ( o.d . ) core study remain dose extension ( double-blind ) . Patients placebo core study receive tegaserod 12 mg o.d . ( open-label ) Patients enter study AFTER core study interim analysis receive select tegaserod dose regimen ( open-label ) determine core study IA .</brief_summary>
	<brief_title>Safety Efficacy Tegaserod Opioid-induced Constipation Patients With Non-cancer Pain .</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>Patient complete 12 week double blind treatment study CHTF919N2201 Planned discontinuation opioids study . Development medical condition list exclusion criterion CHTF919N2201 study . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Opioid , constipation , tegaserod</keyword>
</DOC>